Longitudinal assessment of physical function in adults with X-linked hypophosphatemia following initiation of burosumab therapy
Authors' conclusion
Burosumab treatment is associated with improved lower limb function and mobility at 6 months, with improvement in hand grip strength at 12 months. Future studies should explore the underlying mechanisms and describe on function and other patient outcomes.
Study context
- Population
- Adults with X-linked hypophosphatemia (XLH) initiating burosumab (6 females, age 41.1 ± 15.7 y), specialist centres in London and Bristol5 assessed at 12 months
- Participants
- 10 adults
- Exposure
- Physical function before vs after initiation of burosumab
- Burosumabn = 10
- Outcome
- Physical function and PA, baseline to 6 months
- Follow-up
- 6 months
Methodological detailssingle-group, specialist centres in London and Bristol
- Single-group
- Specialist centres in London and Bristol
Main finding
As reported in the abstract
6 months
Lower limb power (countermovement jump) increased
+9%
P = 0.049
Short physical performance battery (SPPB) score increased
+1.2 points
P = 0.033
Total physical activity (PA) (International Physical Activity Questionnaire (IPAQ)) increased
+65%
P = 0.046
Observational data: associations, not effects.
Further findings
Hand grip strength, 6 to 12 months
- Hand grip significantly improved (only measure to improve between 6 and 12 months)
- +10%, P = 0.023
- Subset of 5 patients
Original publication
Longitudinal assessment of physical function in adults with X-linked hypophosphatemia following initiation of burosumab therapy. Osteoporos Int. Published 19 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →